M&A · Healthcare · Buyer's industry: Biological Products, (No Diagnostic Substances)
Amgen Inc to acquire TENEOBIO
Announced Jul 27, 2021 · Closed Oct 19, 2021 · Private target
Deal value$900M
Premium—To unaffected price
EV / Adj. EBITDA—
ConsiderationAll cash
Transaction
- Acquirer
- Amgen Inc (AMGN)
- Target
- TENEOBIO
- Buyer type
- Strategic
- Offer price per share
- —
- Enterprise value
- —
- Status
- Closed Oct 19, 2021
Deal protections
Not disclosed for private-company acquisitions.
Advisors
- To the acquirer
- Goldman Sachs
- To the target
- Not disclosed
Classification
- Sector
- Healthcare
- Buyer's industry
- Biological Products, (No Diagnostic Substances)